| Prev Close | 7.99 |
| Day Low/High | 8.02 / 9.74 |
| 52 Wk Low/High | 1.55 / 19.39 |
Sorrento Therapeutics, Inc. (SRNE)
9.50
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 262.94B |
| Market Cap | 2.10B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: The Seven Deadly Stock Sins (as Seen on Twitter)
Penny stocks are for suckers, and six other rules for better investing -- and tuning out the tweet noise.
Trade Cautiously With Sorrento Therapeutics
Short-term traders may want to nail down profits and be careful in their trading strategy with this name.
Jim Cramer: What Happens in a Bull Market Is That Stocks Move Up on Nothing
Isaac Newton's first lesson: An object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force.
Jim Cramer: Buyers, It's Time to Look in the Mirror
Blame the Fed? No. I'm reserving my wrath for the clueless buyers who appear to have taken a permanent intellectual summer vacation.
Sorrento Therapeutics Has Made a Large Base Formation - Timing Is Key
The question is when to buy and what to risk.
When a Bus Hits the Equity Market, Learn How to Ride With It
Here are a couple examples of what traders can do to take advantage of those days when stocks take a shellacking.
Sorrento Therapeutics' Wild Swings Are Something I'd Prefer to Miss
The biotech's shares run too hot and cold for this technical analyst's tastes.
There's Plenty of Positive Action But It's a Little Overheated
I'll be watching for entry points to develop this afternoon.
I'm Not Feeling There's Support for a Bounce Now
I'm focused on managing positions and am doing very little new buying at this point.
With an Eye on Biotech, Here's Today's Trading Thesis
It is important to note that watching for a reversal is much different than being short.
Biotech Heats Up as Fear of Missing Out Returns
It's hard to believe the bounce will continue to run in V-shaped fashion.
Seeing Good Action in Several Stocks, Buying More MJ, Gold
It is a very different market environment now which can be very rewarding depending on your style.
Building in Biotech, Adding to Twitter
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
In This Booming Stock Market, Think Like a Programmer Not a Critic
What drives the trading action are structural issues, not macroeconomic news events or political drama.
There Is Still Plenty of Strong, Tradable Action
This market may be extended by just about any measure, but that doesn't mean you should be fighting it.
How Trading Notes Can Increase Your Profits
Inertia is your biggest enemy in this market.
The January Effect Is on Time This Year
I continue to believe that biotech and biopharma stocks will outperform in 2018.
Biotechs Rise and Oil Falls
Stocks remain pretty much flat-lined, with the main indices trading in a very narrow range on light volume. In fact, oil is one of today's few real movers, down nearly 3%. Elsewhere in the markets: Foot Locker is getting a little lift after Citigrou...
